Pfizer Q2 Results Beat Wall Street Expectations; Expects $33B From COVID-19 Vax Sales In 2021

  • Pfizer Inc PFE reports Q2 adjusted EPS of $1.07, well ahead of the consensus of $0.96 and 73% Y/Y higher from $0.62 posted a year ago. 
  • The Company achieved Q2 revenues of $18.9 billion, +92% Y/Y, reflecting operational growth of $8.5 billion, or +86%, surpassing the Wall Street estimate of $18.4 billion.
  • Excluding the COVID-19 vaccine sales of $7.8 billion, revenues grew 10% operationally to $11.1 billion.
  • FY21 Outlook: The Company raised its full-year 2021 revenue outlook to $78 billion - $80 billion (consensus of $72.78 billion), from the prior %70.5 billion - $72.5 billion.
  • It expects EPS of $3.95-$4.05 (consensus- $3.70), higher than the previous outlook of $3.55 - $3.65.
  • Pfizer has raised its revenue expectation from the COVID-19 vaccine by almost $7.5 billion to approximately $33.5 billion, reflecting 2.1 billion doses expected to be delivered in 2021 under signed contracts.
  • Price Action: PFE shares are down 0.21% at $42.01 during the premarket session on the last check Wednesday.
  • Image by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!